CALGARY, AB, May 7, 2024 /CNW/ - Canadabis Capital (TSXV: CANB) with Sub Stigma Grow, a leading Canadian cannabis company, is pleased to announce its strategic expansion into the European market through a significant distribution agreement. This marks a pivotal moment in Stigma Grows history, as the company's innovative products will now be introduced to international markets.
Canadabis Capital emerges into the European Markets (CNW Group/CanadaBis Capital Inc.)
Under this new agreement, Stigma Grow will be distributing its high-quality cannabis products in several key European countries, including Portugal, Germany, and Israel, among others. This move represents a significant milestone for Stigma Grow as it continues to grow its global presence and deliver its cutting edge products to new audiences.
"We are thrilled to announce our entry into the European market through this EU-GMP agreement," said Travis McIntyre, CEO of Canadabis Capital. "This expansion represents a major step forward for our company and underscores our commitment to bringing our cutting-edge products to consumers worldwide."
With a reputation for excellence and a track record of innovation, Stigma Grow is well-positioned to make a significant impact in the European cannabis market. The company's products are known for their quality, consistency, and effectiveness, and have garnered a loyal following in Canada and beyond.
"We believe that our products have the potential to transform the cannabis industry in Europe," added Mcintyre. "We are excited to work with our partners to bring Stigma Grow's unique offerings to customers in Portugal, Germany, Israel, and other European markets. This agreement comes at a time when the world is opening up to Cannabis and we are just getting started."
ABOUT CANADABIS CAPITAL INC.
CanadaBis Capital Inc. (TSXV:CANB) is a vertically integrated Canadian cannabis company focused on achieving large-scale growth, from cultivation to retail, in the fast-emerging global cannabis market. By targeting organic growth opportunities alongside the right-fit partners, we remain focused on finding and capitalizing on chances to grow, diversify and continue to lead our industry.
Our integrated subsidiaries:
Stigma Pharmaceuticals Inc. – 100% held
1998643 Alberta Ltd. (operating as "Stigma Grow") - 100% held; www.stigmagrow.ca
Full Spectrum Labs Ltd. (operating as "Stigma Roots") - 100% held
2103157 Alberta Ltd. -100% held
Goldstream Cannabis Inc. - 95% held
ABOUT STIGMA GROW
Stigma Grow is a cutting-edge cannabis cultivation and extraction company positioned advantageously to meet the unmet market demands and stigmas within the legal cannabis industry head on, with products designed to disturb the status quo and dramatically shift the conversation surrounding Canada's legal cannabis industry.
CAUTIONARY STATEMENTS
Regarding Forward-Looking Information
This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements include but are not limited to statements with respect to our business and operations; the focus of our 2024 activities, our continued cost saving initiatives, our outlook and the plan to seek further growth initiatives. Forward-looking statements are necessarily based upon a number of assumptions including: the ability of the Company's products to compete with the pricing and product availability; the market demand for the Company's products; and assumptions concerning the Company's competitive advantages. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: compliance with extensive government regulation, the general business, economic, competitive, political and social uncertainties; ability to sustain or create a demand for a product; requirement for further capital; delay or failure to receive board, shareholder or regulatory approvals; the results of operations and such other matters as set out in the Company's continuous disclosure on SEDAR at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.
Accordingly, readers should not place undue reliance on forward-looking statements. Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although we believe that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have a material adverse effect on our future results, performance or achievements.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
